These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19836372)

  • 1. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
    Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
    Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
    Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
    J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EGFRvIII variant in glioblastoma multiforme.
    Gan HK; Kaye AH; Luwor RB
    J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
    Chakravarti A; Loeffler JS; Dyson NJ
    Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
    Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
    Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.
    Micallef J; Taccone M; Mukherjee J; Croul S; Busby J; Moran MF; Guha A
    Cancer Res; 2009 Oct; 69(19):7548-56. PubMed ID: 19773446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice.
    Shir A; Ogris M; Wagner E; Levitzki A
    PLoS Med; 2006 Jan; 3(1):e6. PubMed ID: 16318410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
    Reardon DA; Wen PY
    Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
    Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery systems and molecular targets of mechanism-based therapies for GBM.
    Phuphanich S; Brat DJ; Olson JJ
    Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
    Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
    Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
    Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
    Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
    Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
    Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
    Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment strategies for malignant gliomas.
    Sathornsumetee S; Rich JN
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells.
    Hide T; Takezaki T; Nakatani Y; Nakamura H; Kuratsu J; Kondo T
    Stem Cells; 2011 Apr; 29(4):590-9. PubMed ID: 21360625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
    Khalil MY; Grandis JR; Shin DM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
    Adams TE; Koziolek EJ; Hoyne PH; Bentley JD; Lu L; Lovrecz G; Ward CW; Lee FT; Scott AM; Nash AD; Rothacker J; Nice EC; Burgess AW; Johns TG
    Growth Factors; 2009 Jun; 27(3):141-54. PubMed ID: 19333814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.